Literature DB >> 23819994

Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years.

Bo Liu1, Xin Wen, Canhua Huang, Yuquan Wei.   

Abstract

Hepatitis B virus (HBV) is a well-known hepadnavirus with a double-stranded circular DNA genome. Although HBV was first described approximately 50 years ago, the precise mechanisms of HBV infection and effective therapeutic strategies remain unclear. Here, we focus on summarizing the complicated mechanisms of HBV replication and infection, as well as genomic factors and epigenetic regulation. Additionally, we discuss in vivo models of HBV, as well as diagnosis, prevention and therapeutic drugs for HBV. Together, the data in this 50-year review may provide new clues to elucidate molecular mechanisms of HBV pathogenesis and shed new light on the future HBV therapies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated; 5-LOX; 5-lipoxygenase; AFP; ALDH1; ALL; ALT; AR; AST; C/EBP-β; CCAAT enhancer binding protein β; CD8T lymphocytes; CDH1; CHB; CIITA; CP; CREB; CRHR2; CTLs; CXCR1; DDC; DTP; FAK; FDA; FXRA; Food and Drug Administration; HB; HBIG; HBV; HBV therapy; HBcAg; HBeAg; HBsAg; HBx; HBx protein; HCC; HDAC1; HO-1; Heme oxygenase-1; Hepatitis B virus; Hepatocellular carcinoma; IFN-α; IFNAR1; IL; In vivo model; JAK; Janus kinase; MAPK; MMF; MTA1; NHP; OPN; ORFs; PC; PEG; PH; PKC; PP1; PPIs; RNA interference; RNAi; SNPs; SPP1; STAT; TATA binding protein; TBP; TGF; TNF; WHV; alanine aminotransferase; aldehyde dehydrogenase 1; androgen receptor; aspartate aminotransferase; cadherin-1; cccDNA; chemokine (C-X-C motif) receptor 1; chronic hepatitis B; class II transactivator; core promoter; corticotropin-releasing hormone receptor 2; covalently closed circular DNA; cyclic adenosine monophosphate (cAMP) response element-binding protein; diphtheria–tetanus–pertussis; farnesoid X receptor alpha; focal adhesion kinase; hepatitis B; hepatitis B X protein; hepatitis B core antigen; hepatitis B e antigen; hepatitis B immune globulin; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; heterogeneous nuclear ribonucleoproteins K; histone deacetylase 1; hnRNP K; interferon alpha; interleukin; lymphoblastic leukemia; macrophagic myofasciitis; metastasis-associated protein 1; miRNA; microRNA; mitogen-activated protein kinase; non-human primates; open reading frames; osteopontin; polyethylene glycol; portal hypertension; precore; protein kinase C; protein phosphatase 1; protein–protein interactions; secreted phosphoprotein-1; signal transducer and activator of transcription; single nucleotide polymorphisms; transforming growth factor; tumor necrosis factor; type I interferon (IFN-alpha/beta) receptor 1; woodchuck hepatitis virus; α-fetoprotein

Mesh:

Substances:

Year:  2013        PMID: 23819994     DOI: 10.1016/j.biocel.2013.06.017

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

1.  The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription.

Authors:  Zhenning Tan; Karolyn Pionek; Nuruddin Unchwaniwala; Megan L Maguire; Daniel D Loeb; Adam Zlotnick
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

2.  Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4.

Authors:  Joel Celio Francisco; Qian Dai; Zhuojuan Luo; Yan Wang; Roxanne Hui-Heng Chong; Yee Joo Tan; Wei Xie; Guan-Huei Lee; Chengqi Lin
Journal:  Mol Cell Biol       Date:  2017-09-12       Impact factor: 4.272

3.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

4.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

5.  Hepatitis B Virus Capsids Have Diverse Structural Responses to Small-Molecule Ligands Bound to the Heteroaryldihydropyrimidine Pocket.

Authors:  Balasubramanian Venkatakrishnan; Sarah P Katen; Samson Francis; Srinivas Chirapu; M G Finn; Adam Zlotnick
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 6.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

Review 7.  Mechanism of Hepatocyte Apoptosis.

Authors:  Lei Cao; Xi-Bing Quan; Wen-Jiao Zeng; Xiao-Ou Yang; Ming-Jie Wang
Journal:  J Cell Death       Date:  2016-12-29

Review 8.  Battle of the sexes: contrasting roles of testis-specific protein Y-encoded (TSPY) and TSPX in human oncogenesis.

Authors:  Yun-Fai Chris Lau; Yunmin Li; Tatsuo Kido
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

Review 9.  The androgen receptor as an emerging target in hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Osamu Yokosuka
Journal:  J Hepatocell Carcinoma       Date:  2015-06-26

10.  Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.

Authors:  Vinayaka Kotraiah; Timothy W Phares; Cecille D Browne; James Pannucci; Marc Mansour; Amy R Noe; Kenneth D Tucker; Jayne M Christen; Charles Reed; Alecia MacKay; Genevieve M Weir; Rajkannan Rajagopalan; Marianne M Stanford; Chun-Shiang Chung; Alfred Ayala; Jing Huang; Moriya Tsuji; Gabriel M Gutierrez
Journal:  Front Immunol       Date:  2020-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.